Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Todd N. Eagar

Todd N. Eagar, Ph.D.

Associate Medical Director, Histocompatibility and Transplant Immunology
Department of Pathology and Genomic Medicine
Houston Methodist Hospital Physician Organization

6565 Fannin Street, Suite M227
Houston, Texas 77030
Phone: 713-441-4669
Email: tneagar@houstonmethodist.org


Dr. Eagar received his Ph.D. in immunology and molecular pathogenesis from the Northwestern University Medical School in Chicago, Illinois in 2001. He then completed an immunology fellowship at the University of California at San Francisco and a HLA fellowship at Houston Methodist Hospital in Houston, Texas. Dr. Eagar was an assistant professor in the Department of Pathology and Immunology at The University of Texas Southwestern Medical Center in Dallas before joining Houston Methodist Hospital Physician Organization in 2013.

Dr. Eagar is certified in histocompatibility by the American Board of Histocompatibility and Immunogenetics. His research interests include identifying immune processes involved in the pathogenesis of multiple sclerosis and transplant rejection, with a focus on finding novel regulatory pathways involved in T cell activation that might be harnessed for therapeutic intervention.

Representative Recent Publications

  • Lambracht-Washington D, Qu BX, Fu M, Anderson LD Jr, Eagar TN, Stüve O, Rosenberg RN. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aß42 DNA vaccine for Alzheimer disease. J Neuroimmunol. 2013 Jan 15;254(1-2):63-8.
  • Cravens PD, Hussain RZ, Zacharias TE, Ben LH, Herndon E, Vinnakota R, Lambracht-Washington D, Nessler S, Zamvil SS, Eagar TN, Stüve O. Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet. J Neuroinflammation. 2011 Jun 24;8:73.
  • Lambracht-Washington D, Qu BX, Fu M, Anderson LD Jr, Stüve O, Eagar TN, Rosenberg RN. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. Cell Mol Neurobiol. 2011 Aug;31(6):867-74.
  • Monson NL, Cravens P, Hussain R, Harp CT, Cummings M, de Pilar Martin M, Ben LH, Do J, Lyons JA, Lovette-Racke A, Cross AH, Racke MK, Stüve O, Shlomchik M, Eagar TN. Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS One. 2011 Feb 16;6(2):e17103.
  • Pacheco MF, Jacobe H, Eagar TN, Stüve O. Reversible alopecia associated with glatiramer acetate. Arch Neurol. 2010 Sep;67(9):1154.
  • Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, Cravens PD, Stuve O, Lovett-Racke AE, Eagar TN, Greenberg BM, Racke MK, Cowell LG, Karandikar NJ, Frohman EM, Monson NL. Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-? production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol. 2010 Oct;40(10):2942-56.
  • Stüve O, Kieseier BC, Hemmer B, Hartung HP, Awad A, Frohman EM, Greenberg BM, Racke MK, Zamvil SS, Phillips JT, Gold R, Chan A, Zettl U, Milo R, Marder E, Khan O, Eagar TN. Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol. 2010 Nov;67(11):1307-15.
  • Qu BX, Lambracht-Washington D, Fu M, Eagar TN, Stüve O, Rosenberg RN. Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease. Vaccine. 2010 Jul 19;28(32):5280-7.
  • Hu W, Nessler S, Hemmer B, Eagar TN, Kane LP, Leliveld SR, Müller-Schiffmann A, Gocke AR, Lovett-Racke A, Ben LH, Hussain RZ, Breil A, Elliott JL, Puttaparthi K, Cravens PD, Singh MP, Petsch B, Stitz L, Racke MK, Korth C, Stüve O. Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling. Brain. 2010 Feb;133(Pt 2):375-88.